Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Erlotinib in Metastatic Pancreatic Adenocarcinoma
NCT03213626Phase 2Terminated
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in pancreatic adenocarcinoma (PDAC). Started Oct 2017; status: terminated.
02
Drugs
cabozantinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03213626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213626.